共 17 条
[11]
Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T., Biomarkers associated with COVID-19 disease progression, Crit Rev Clin Lab Sci, 57, pp. 389-399, (2020)
[12]
Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Et al., Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China, Clin Infect Dis, 71, pp. 762-768, (2020)
[13]
Deng Y, Liu W, Liu K, Fang Y-Y, Shang J, Zhou L, Wang K, Leng F, Wei S, Chen L, Et al., Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study, Chin Med J (Engl), 133, pp. 1261-1267, (2020)
[14]
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Et al., Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China Supplemental content, JAMA Intern Med, 180, pp. 934-943, (2020)
[15]
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, pp. 1054-1062, (2020)
[16]
Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Et al., Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogene-sis in Covid-19, N Engl J Med, 383, pp. 120-128, (2020)
[17]
McGonagle D, O'Donnell JS, Sharif K, Emery P, Bridgewood C., Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia, Lancet Rheumatol, 2, pp. e437-e445, (2020)